Primary Raynaud's Phenomenon: What to Do When Oral Vasodilator Therapy Has Not Controlled Attacks

Some patients with primary Raynaud's phenomenon do not achieve adequate reduction in attack frequency, severity, or duration despite oral therapy. A structured next-line protocol addresses this gap with a different treatment strategy.

Prior Therapy That Did Not Work

This protocol is indicated after treatment with oral agents — sildenafil, tadalafil, losartan, fluoxetine, or prazosin — has failed to reach the goals of reducing the frequency, severity, and duration of Raynaud's attacks and improving the Raynaud's Condition Score.

Clinical Goal

The objective of this next-line protocol is measurable improvement in the Raynaud's Condition Score.

Treatment Approach (Partial Overview)

This protocol involves a topical vasodilator applied directly to the fingers, timed to the onset of a Raynaud's attack. The complete regimen — including the specific agent or agents, precise application detail, and full clinical algorithm — is available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1177/1759720X17740074

Glyceryl trinitrate (GTN) patches can be prescribed for their systemic vasodilatory effects, but are often poorly tolerated.
A multicentre, placebo-controlled trial demonstrated benefit from a novel formulation of GTN, MQX-503, in terms of improvement in Raynaud's Condition Score.
MQX-503 gel was applied to the fingers immediately before or within 5 min of onset of a Raynaud's attack over a 4-week period.

View source ↗